Hims Sales Miss on Rising Competition for Weight-Loss Drugs

Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates amid increasing competition in the weight-loss drug market.

Revenue was $608 million, the company said in a statement Monday, below the average analyst estimate of $617.5 million. The company reported a loss of 40 cents a share in the period, compared with profit of 20 cents a share a year ago.